Arohi Asset Management PTE Ltd. Has $16.21 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

Arohi Asset Management PTE Ltd. boosted its stake in Illumina, Inc. (NASDAQ:ILMN) by 91.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 121,270 shares of the life sciences company’s stock after acquiring an additional 58,070 shares during the period. Illumina accounts for 4.4% of Arohi Asset Management PTE Ltd.’s investment portfolio, making the stock its 4th largest holding. Arohi Asset Management PTE Ltd. owned about 0.08% of Illumina worth $16,205,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ILMN. Keel Point LLC bought a new stake in shares of Illumina in the 4th quarter valued at $204,000. Ion Asset Management Ltd. boosted its position in Illumina by 10.9% during the fourth quarter. Ion Asset Management Ltd. now owns 800,500 shares of the life sciences company’s stock valued at $106,971,000 after acquiring an additional 79,001 shares during the last quarter. Perbak Capital Partners LLP acquired a new stake in Illumina during the 4th quarter worth about $1,201,000. Lido Advisors LLC raised its position in shares of Illumina by 18.1% in the 4th quarter. Lido Advisors LLC now owns 3,392 shares of the life sciences company’s stock worth $453,000 after acquiring an additional 521 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Illumina by 26.9% in the 4th quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company’s stock valued at $220,882,000 after purchasing an additional 349,878 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the subject of several recent analyst reports. TD Cowen cut Illumina from a “buy” rating to a “hold” rating and decreased their target price for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. Robert W. Baird lowered their price objective on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. Morgan Stanley cut their target price on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Citigroup decreased their price target on shares of Illumina from $90.00 to $85.00 and set a “neutral” rating for the company in a research note on Monday, April 7th. Finally, Piper Sandler increased their price objective on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Illumina presently has an average rating of “Moderate Buy” and a consensus price target of $137.55.

Illumina Trading Up 1.8 %

Shares of ILMN stock opened at $77.88 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company has a market capitalization of $12.33 billion, a price-to-earnings ratio of -10.14, a PEG ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The company has a 50-day simple moving average of $80.07 and a two-hundred day simple moving average of $115.86.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.